OCALA, FL / ACCESSWIRE / August 25, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at The LD 500 Investor conference being held virtually on September 1-4, 2020.
Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to present on Tuesday, September 1st at 1:20 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here. One-on-one meetings will be held throughout the conference via video conference calls.
The LD 500 will feature the most prominent companies in the small and micro-cap world, alongside interviews and keynotes with thought leaders from various industries.
To schedule a one-on-one meeting with AIM ImmunoTech, you may submit your request online via the link provided upon registration or email your request to [email protected]. To register for the conference, contact David Scher at [email protected] or visit https://ld-micro-conference.events.issuerdirect.com/.
View AIM ImmunoTech's LD Micro profile here: https://www.ldmicro.com/profile/aim
Profiles powered by LD Micro - News Compliments of Accesswire
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: [email protected]
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: [email protected]
SOURCE: AIM ImmunoTech via LD Micro